Tustin, CA – Integrium Executives will be in Boston for the 2017 Microbiome Drug Development Summit on June 27-29. Intrigued by the summits' information-filled approach, Integrium Executives are looking forward to gaining access to microbiome clinical information to broaden the future in this rapidly changing therapeutic area.
The summit consists of a wide range of topics discussed around microbiome drug development and the future of clinical advancement. Being that the microbiome plays a huge role in our overall health, the need for finding discoveries to help cure diseases is never-ending. The Microbiome Drug Development Summit allows key industry leaders to collaborate with like-minded people and companies that share a common goal and overall advance microbiome medicine.
“Although we have been conducting Microbiome clinical trials for years, we always want to learn more about the microbiome and how to best go about designing safe and effective clinical trials; which gives Integrium the knowledge and understanding to tackle these new, cutting-edge opportunities,” mentioned Mike Loftus, Executive Director of Business Development. Hearing from the clinical side of the microbiome field helps Integrium target their microbiome services to the right companies that are in the market for these unique set of skills.
Integrium Executives are looking forward to being involved in workshops and hearing from speakers that will discuss improving preclinical models for microbiome drug discovery, key factors to designing safe and effective clinical trials, raising investments to advance therapeutic efforts, and more. Having access to the latest information in the microbiome field will provide Integrium with the knowledge to tackle the challenges that exist in the pharmaceutical industry today.
Integrium Executives will be taking meetings throughout the summit and encourage guests to schedule meeting requests with Emily MacHale at Emily.MacHale@integrium.com. We look forward to seeing you there!
Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Innovator and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs
Check out our new website!
To learn more about Integrium, LLC, please contact:
Associate Director, Marketing